Accessibility / Report Error

In vitro susceptibility of Paracoccidioides brasiliensis yeast form to antifungal agents

Susceptibilidad in vitro de la forma levaduriforme de Paracoccidioides brasiliensis a los agentes antifungicos

Angela Restrepo Catalina de Bedoutand Angela M. Tabares About the authors

Abstracts

A study was conducted to determine the susceptibility of P. brasiliensis yeast form to amphotericin B (A), ketoconazole (K), 5-fluorocytosine (5-FC) and rifampin (R). The three isolates tested produced minimal inhibitory concentrations (MICs) (mcg/ml) in the following range: A: 0.09-0.18; K: 0.001-0.007; 5-FC: 62.5-250 and R: 40-80. The minimal fungicidal concentrations (MFC) were several times higher than the corresponding MICs. Precise MFC for 5-FC were not obtained (> 500 mcg/ml). Combination of K plus A proved synergic, with the fractional inhibitory concentration (FIC) indices revealing synergy when the drugs were combined at the 1 to 1 and 1 to 5 MIC ratios. R (40 mcg/ml) appeared to antagonize K. These results indicate promise for the combined use of K plus A as a therapeutical regimen.


Se realizó un estudio con el objeto de determinar la susceptibilidad de la fase levaduri-forme del P. brasiliensis a la Anfotericina B (A), el Ketoconazol (K), la 5-fluorocitosina (5-FC) y la rifampicina. Las 3 cepas estudiadas tuvieron las siguientes concentraciones inhibitorias mínimas (MIC) (mcg/ml) A: 0.09-0.18; K: 0.001-0.007; 5-FC: 62.5-250 y R: 40-80. Las concentraciones fungicidas mínimas (MFC) resultaron más altas que las MICs correspondientes. En el caso de la 5-FC no se obtuvo una cifra MFC precisa (> 500 mcg/ml). La combinación de K más A mostró ser sinérgica al combinarse las drogas en relación 1:1 y 1:5 de los MICs respectivos. R (40 mcg/ml) se mostró antagonista del K. Los resultados indican que la combinación A + K pudiera constituir un adecuado régimen terapéutico en ciertos pacientes.


In vitro susceptibility of Paracoccidioides brasiliensis yeast form to antifungal agents

Susceptibilidad in vitro de la forma levaduriforme de Paracoccidioides brasiliensis a los agentes antifungicos

Angela Restrepo; Catalina de Bedoutand Angela M. Tabares

Corporación de Investigaciones Biológicas, Hospital Pablo Tobón Uribe, Medellín, Colombia

SUMMARY

A study was conducted to determine the susceptibility of P. brasiliensis yeast form to amphotericin B (A), ketoconazole (K), 5-fluorocytosine (5-FC) and rifampin (R). The three isolates tested produced minimal inhibitory concentrations (MICs) (mcg/ml) in the following range: A: 0.09-0.18; K: 0.001-0.007; 5-FC: 62.5-250 and R: 40-80. The minimal fungicidal concentrations (MFC) were several times higher than the corresponding MICs. Precise MFC for 5-FC were not obtained (> 500 mcg/ml). Combination of K plus A proved synergic, with the fractional inhibitory concentration (FIC) indices revealing synergy when the drugs were combined at the 1 to 1 and 1 to 5 MIC ratios. R (40 mcg/ml) appeared to antagonize K. These results indicate promise for the combined use of K plus A as a therapeutical regimen.

RESUMEN

Se realizó un estudio con el objeto de determinar la susceptibilidad de la fase levaduri-forme del P. brasiliensis a la Anfotericina B (A), el Ketoconazol (K), la 5-fluorocitosina (5-FC) y la rifampicina. Las 3 cepas estudiadas tuvieron las siguientes concentraciones inhibitorias mínimas (MIC) (mcg/ml) A: 0.09-0.18; K: 0.001-0.007; 5-FC: 62.5-250 y R: 40-80. Las concentraciones fungicidas mínimas (MFC) resultaron más altas que las MICs correspondientes. En el caso de la 5-FC no se obtuvo una cifra MFC precisa (> 500 mcg/ml). La combinación de K más A mostró ser sinérgica al combinarse las drogas en relación 1:1 y 1:5 de los MICs respectivos. R (40 mcg/ml) se mostró antagonista del K. Los resultados indican que la combinación A + K pudiera constituir un adecuado régimen terapéutico en ciertos pacientes.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

ACKNOWLEDGEMENTS

This work was supported by the Fondo Colombiano de Investigaciones Científicas (Col-ciencias), Bogotá, (Project Nr. 97145-3-04-80).

Recebido para publicação em 13/2/1984.

  • 1. BENNET, J. E.; DISMUKES, W. E.; DUMA, R. J.; MEDOFF, G. et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New England J. Med. 301: 126-131, 1979.
  • 2. BORELLI, D.; BRAN, J. L.; FUENTES, J.; LEGENDRE, R.; LEIDERMAN, E.; LEVINE, H. B.; RESTREPO, A. & STEVENS, D. A. Laboratory and clinical assessment of imidazole drugs. Post-grad. Med. J. 55: 657-661, 1979.
  • 3. DEL NEGRO, G. Tratamento, controle de cura, profilaxia, pp. 271-281 in Paracoccidioidomicose DEL NEGRO, G.; LACAZ, C. S. & FIORILLO, A. M. (Editors). São Paulo, Sarvier, 1982.
  • 4. DOUGHERTY, P. F.; YOTTER, D. W. & MATTHEWS, T. R. Chemically defined medium for susceptibility testing of antimicrobial agents. Antimicrob. Agents Chemother. 10: 923-925, 1976.
  • 5. DROUHET, E. & DUPONT, B. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am. J. Med. 74 (Suppl.): 30-47, 1983.
  • 6. ELION, G. B.; SINGERAND, S. & HITCHINGS, G. H. Antagonism of nucleic acid derivatives. J. Biol. Chem. 208: 477-488, 1954.
  • 7. GALGIANI, J. N. & STEVENS, D. A. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob. Agents Chemother. 10: 721-726, 1976.
  • 8. LACAZ, C. S.; ULSON, C. M. & SAMPAIO, S. A. P. Ação in vitro da anfotericina B sobre o P. brasiliensis. Rev. Paul. Med. 54: 357-360, 1959.
  • 9. LACAZ, C. S.; MINAMI, P. S. & FERNÁNDEZ, W. Ação in vitro de sulfametoxipiridazina sobre fungos patogênicos. Hospital (Rio) 73: 15-22, 1968.
  • 10. MOODY, M. R.; YOUNG, W. M.; MORRIS, M_. J. & SCHIMPFF, S. C. In vitro activities of micona- zole, miconazole nitrate, and ketoconazole alone and combined with rifampin Candida spp and T. glabrata recovered from cancer patients. Antimicrob. Agents Chemother. 17: 871-875, 1980.
  • 11. ODDS, P. C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole and miconazole against pathogenic fungi in vitro. Anthnicrob. Agents Chemother. 22: 763-770, 1982.
  • 12. RESTREPO, A. & ARAN GO, M. D. In vitro susceptibility testing of P. brasiliensis to sulfonamides. Anthnicrob. Agents Chemother. 18: 190-194, 1980.
  • 13. RESTREPO, A. & JIMÉNEZ, B. E. Growth of P. brasiliensis yeast phase in a chemically defined culture medium. J. Clin. Microbiol. 12: 279-281, 1980.
  • 14. RESTREPO, A.; STEVENS, D. A.; GOMEZ, I.; LEI-DERMAN, E.; ANGEL, R.; FUENTES, J.; ARANA, A.; MEJÍA, G.; VANEGAS, A. C. & ROBLEDO, M. A. Ketoconazole: a new drug for the treatment of paracoccidioidomycosis. Rev. Infect. Dis. 2: 633-«42, 1980.
  • 15. RESTREPO, A. & CANO, L. E. Recovery of fungi from seeded sputum samples. Effect of culture media and digestion procedures. Rev. Inst. Med. trop. São Paulo 23: 139-184, 1981.
  • 16. SHADOMY, S. & ESPINEL-INGROFF, A. Susceptibility testing with antifugal drugs, pp. 647-653. In LENNETTE, E. H.; BALOWS, A.; HAUSLER, W. J. & TRUANT, J. P. (Ed.). Manual of Clinical Microbiology. 3rd. Washington, ASM, 1980.
  • 17. STEVENS, D. A. & VO, P. T. Synergic interaction of trimethoprim sulfamethoxazole on P. brasiliensis. Anthnicrob. Agents Chemother. 21: 852-854, 1982.

Publication Dates

  • Publication in this collection
    04 Apr 2013
  • Date of issue
    Dec 1984

History

  • Received
    13 Feb 1984
Instituto de Medicina Tropical de São Paulo Av. Dr. Enéas de Carvalho Aguiar, 470, 05403-000 - São Paulo - SP - Brazil, Tel. +55 11 3061-7005 - São Paulo - SP - Brazil
E-mail: revimtsp@usp.br